Turkey Researchers Find CoronaVac COVID-19 Vaccine Very Effective
Researchers at the Manisa Celal Bayar University (MCBU) Medical Faculty Hospital in the Republic of Turkey completed the first comprehensive, local study of the 'immune response to the SARS CoV-2 Inactive (Sinovac-Coronavac) vaccine.
Between early January and March 18, 2021, researchers ran tests among 1,053 people without SARS-CoV-2 antibodies. All were health care workers who were prioritized in the country’s inoculation campaign.
In a media statement issued on April 5, 2021, the researchers stated, "After the first vaccine, there is not enough immunity, and after the second vaccine, an inactive vaccine boosts immunity to 99%.
Dr. Şebnem Şenlo Akar emphasized that the vaccine has an antibody development rate of 97% in men and 99% in women. "We have created immunity in a large part of the society."
The rate of people suffering from slight side effects like pain in the spot where the vaccine is administered and a headache was below 25%. “Serious side effects were below 1%,” researchers said.
The scientific study on the Sinovac-Coronavac Vaccine' was conducted by the academic staff of the Department of Infectious Diseases, Public Health and Medical Microbiology of Manisa CBU Faculty of Medicine.
